Chen Z X, Chen J M, Geng X P, Liu F B
Department of Hepatobiliary and Pancreatic Surgery,the First Affiliated Hospital of Anhui Medical University, Hefei 230001, China.
Zhonghua Wai Ke Za Zhi. 2024 Jul 1;62(7):665-670. doi: 10.3760/cma.j.cn112139-20240103-00003.
The incidence and mortality rate of hepatocellular carcinoma rank among the top of all cancer types,seriously threatening the life and health of human beings. In recent years,the rapid development of artificial intelligence and the deepening of the concept of precision medicine have led to a boom in interdisciplinary research. Pathomics,as an emerging omics technology driven by artificial intelligence,can mine massive information from high-resolution whole slide images,and shows broad application prospects in the diagnosis,treatment and prognosis assessment of hepatocellular carcinoma. However, pathomics research in hepatocellular carcinoma is still in its infancy, and its research patterns and clinical applications still face several controversies and challenges, including data security, ethics, and "black box" issues. Future research should focus on conducting prospective studies, integrating multimodal data, improving computational technologies, and establishing professional standards to promote the high-quality development of pathomics technology in both clinical and basic research of hepatocellular carcinoma.
肝细胞癌的发病率和死亡率在所有癌症类型中位居前列，严重威胁着人类的生命健康。近年来，人工智能的快速发展和精准医学概念的不断深入，引发了跨学科研究的热潮。病理组学作为一种由人工智能驱动的新兴组学技术，能够从高分辨率全切片图像中挖掘海量信息，在肝细胞癌的诊断、治疗及预后评估中展现出广阔的应用前景。然而，肝细胞癌的病理组学研究仍处于起步阶段，其研究模式和临床应用仍面临诸多争议和挑战，包括数据安全、伦理以及“黑箱”问题。未来的研究应聚焦于开展前瞻性研究、整合多模态数据、改进计算技术并建立专业标准，以推动病理组学技术在肝细胞癌临床和基础研究中的高质量发展。
